Claims

Claims 1-11 (Canceled).

Claim 12 (Currently Amended): A method of delivering a substance to microtubules, comprising exposing said microtubules to said substance, said substance being in a form selected from the group consisting of a fusion, a covalent coupling, and a non-covalent association, of said substance with a protein, wherein said protein is a herpes simplex virus 1 (HSV1) VP22 protein, or is a portion thereof which binds microtubules comprising amino acids 1 to 267 of HSV1 VP22 protein, amino acids 1 to 191 of HSV1 VP22 protein, or amino acids 1 to 172 of HSV1 VP22 protein, and wherein said substance is a microtubule binding substance drug.

Claim 13-16 (Canceled).

Claim 17 (Previously Presented): The method of claim 12, wherein the substance is taxol.

Claim 18 (Canceled).

Claim 19 (New): The method of claim 1, wherein said protein comprises amino acids 1 to 267 of HSV1 VP22 protein.

Claim 20 (New): The method of claim 1, wherein said protein comprises amino acids 1 to 191 of VP22 protein.

Claim 21 (New): The method of claim 1, wherein said protein comprises amino acids 1 to 172 of VP22 protein.